MedTrace Logo

Azithromycin for Meibomian Gland Disease

NCT03953118 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2025-08-06

Study results available
· View outcomes & findings →

Summary

This study aims to elucidate the effectiveness of oral azithromycin in treating symptomatic dry eye syndrome secondary to Meibomian gland dysfunction.

Conditions

  • Dry Eye
  • Neuropathic Eye Pain
  • Ocular Microbiome
  • Depression, Anxiety

Interventions

DRUG

Azithromycin Oral Product

Oral azithromycin dosed at 1 gram per week for 3 weeks

DRUG

Placebo Oral

Oral placebo tablet

Sponsors & Collaborators

Principal Investigators

  • Julie Schallhorn, MD, MS · University of California, San Francisco

  • Thuy Doan, MD, PhD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2021-07-01
Completion
2021-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03953118 on ClinicalTrials.gov